Xenetic Biosciences Inc (XBIO)

Apr 9, 2025, 9:15 AM EDT - 11 days ago

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

Mar 26, 2025, 9:00 AM EDT - 25 days ago

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma

Mar 19, 2025, 8:05 AM EDT - 4 weeks ago

Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results

Mar 13, 2025, 8:30 AM EDT - 5 weeks ago

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses

Feb 27, 2025, 9:15 AM EST - 7 weeks ago

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting

Dec 16, 2024, 9:00 AM EST - 4 months ago

Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

Dec 5, 2024, 8:45 AM EST - 4 months ago

Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program

Nov 21, 2024, 8:30 AM EST - 5 months ago

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis

Nov 13, 2024, 8:30 AM EST - 5 months ago

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 9:00 AM EST - 5 months ago

Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models

Nov 7, 2024, 9:00 AM EST - 5 months ago

Xenetic Biosciences, Inc. Extends Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Oct 22, 2024, 8:45 AM EDT - 6 months ago

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

Oct 17, 2024, 8:45 AM EDT - 6 months ago

Xenetic Biosciences, Inc. Enters into Materials Transfer Agreement with Tokyo Medical University for the Advancement of Its DNase-Based Oncology Platform

Sep 11, 2024, 9:00 AM EDT - 7 months ago

Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 8:00 AM EDT - 8 months ago

Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

May 10, 2024, 8:30 AM EDT - 1 year ago

Xenetic Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

Mar 22, 2024, 8:00 AM EDT - 1 year ago

Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results

Jan 17, 2024, 9:00 AM EST - 1 year ago

Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform

Nov 10, 2023, 8:35 AM EST - 1 year ago

Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial Results

Oct 11, 2023, 9:05 AM EDT - 1 year ago

Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference

Sep 5, 2023, 8:05 AM EDT - 1 year ago

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 11, 2023, 8:05 AM EDT - 1 year ago

Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial Results

Jul 5, 2023, 8:45 AM EDT - 1 year ago

Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight Series

May 12, 2023, 12:30 PM EDT - 2 years ago

Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock

May 11, 2023, 4:30 PM EDT - 2 years ago

Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

May 4, 2023, 8:35 AM EDT - 2 years ago

Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D.

May 3, 2023, 8:35 AM EDT - 2 years ago

Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison

Apr 11, 2023, 8:30 AM EDT - 2 years ago

Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

Mar 23, 2023, 7:35 AM EDT - 2 years ago

Xenetic Biosciences, Inc. Reports Full Year 2022 Financial Results and Provides Business Update

Mar 16, 2023, 11:00 AM EDT - 2 years ago

JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciences

Mar 16, 2023, 8:05 AM EDT - 2 years ago

Xenetic Biosciences, Inc. to Present at the Virtual Investor NETs in Cancer Spotlight Event

Jan 17, 2023, 8:05 AM EST - 2 years ago

Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy

Jan 5, 2023, 8:05 AM EST - 2 years ago

Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch Event

Nov 16, 2022, 8:35 AM EST - 2 years ago

Xenetic Biosciences, Inc. Engages Leading NETs Research Expert, Jonathan Spicer, MD, PhD for Advancement of DNase Oncology Platform

Nov 10, 2022, 7:05 AM EST - 2 years ago

Xenetic Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update

Oct 11, 2022, 8:05 AM EDT - 2 years ago

Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics

VNRX

Oct 4, 2022, 8:00 AM EDT - 2 years ago

Xenetic Biosciences, Inc. Appoints Globally Recognized Oncology Leader, Allan Tsung, MD to its Scientific Advisory Board

Sep 7, 2022, 8:05 AM EDT - 2 years ago

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Aug 12, 2022, 8:00 AM EDT - 2 years ago

Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

Aug 2, 2022, 8:05 AM EDT - 2 years ago

Xenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of Cancer

VNRX

Jul 7, 2022, 9:00 AM EDT - 3 years ago

Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study

Jun 2, 2022, 2:00 PM EDT - 3 years ago

JTC Team to Host Virtual Investor Innovation in Oncology Featuring Xenetic Biosciences

Jun 2, 2022, 8:35 AM EDT - 3 years ago

Xenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology Event

May 18, 2022, 8:15 AM EDT - 3 years ago

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment Conference

May 12, 2022, 4:05 PM EDT - 3 years ago

Xenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

Apr 27, 2022, 6:30 AM EDT - 3 years ago

Xenetic Biosciences, Inc. Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Multiple Therapeutic Modalities

Mar 23, 2022, 8:30 AM EDT - 3 years ago

Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update

Nov 12, 2021, 8:00 AM EST - 3 years ago

Xenetic Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

Sep 9, 2021, 8:05 AM EDT - 3 years ago

Xenetic Biosciences, Inc. Receives Notice of Allowance for XCART(TM) Patent

Sep 8, 2021, 8:00 AM EDT - 3 years ago

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference